Treace Medical Concepts (TMCI)
(Real Time Quote from BATS)
$5.95 USD
+0.15 (2.59%)
Updated Sep 27, 2024 12:54 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Treace Medical Concepts, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 187 | 142 | 94 | 57 | 39 |
Cost Of Goods | 35 | 28 | 18 | 12 | 8 |
Gross Profit | 152 | 114 | 77 | 45 | 32 |
Selling & Adminstrative & Depr. & Amort Expenses | 203 | 149 | 93 | 44 | 35 |
Income After Depreciation & Amortization | -51 | -35 | -17 | 1 | -4 |
Non-Operating Income | 7 | -4 | 0 | -2 | 0 |
Interest Expense | 5 | 4 | 4 | 3 | 1 |
Pretax Income | -50 | -43 | -21 | -4 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -50 | -43 | -21 | -4 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -50 | -43 | -21 | -4 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -47 | -33 | -16 | 2 | -3 |
Depreciation & Amortization (Cash Flow) | 4 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -51 | -35 | -17 | 1 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.85 | 55.28 | 48.42 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.81 | -0.69 | -0.43 | NA | NA |
Diluted Net EPS (GAAP) | -0.81 | -0.77 | -0.43 | NA | NA |
Fiscal Year end for Treace Medical Concepts, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 44.46 | 51.11 | 62.21 | 40.76 | 41.95 |
Cost Of Goods | 8.78 | 10.13 | 11.47 | 8.00 | 7.68 |
Gross Profit | 35.67 | 40.98 | 50.74 | 32.76 | 34.28 |
SG&A, R&D, and Dept/Amort Expenses | 57.06 | 59.95 | 57.52 | 50.58 | 47.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -21.39 | -18.97 | -6.78 | -17.82 | -13.05 |
Non-Operating Income | 1.49 | 1.61 | 1.81 | 1.59 | 2.06 |
Interest Expense | 1.31 | 1.32 | 1.30 | 1.30 | 1.28 |
Pretax Income | -21.21 | -18.68 | -6.28 | -17.52 | -12.27 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.21 | -18.68 | -6.28 | -17.52 | -12.27 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.21 | -18.68 | -6.28 | -17.52 | -12.27 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 62.08 | 61.79 | 61.70 | 61.56 | 61.38 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.30 | -0.10 | -0.28 | -0.20 |
Diluted Net EPS (GAAP) | -0.34 | -0.30 | -0.10 | -0.28 | -0.20 |